Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin for Liver Inflammation and Lipoprotein Metabolism in T2DM with NAFLD
NCT05422092Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Sep 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
01
Overview
Randomised trial of canagliflozin in non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Plasma cholesteryl ester transfer protein concentration at 24 weeks and Plasma cholesteryl ester transfer protein activity at 24 weeks. Status: unknown.
02
Drugs
canagliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05422092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05422092.